login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Genous stent is a safe and effective option in STEMI patients


Friday, 09 Mar 2012 09:26
Genous
Genous

OrbusNeich has reported clinical data showing that the Genous stent is safe and effective for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Published in Revista Española de Cardiología, the data from the GENIA study show low rates of stent thrombosis and target lesion revascularisation at a mean follow-up of 538 ± 334.72 days.


In the prospective observational study, which included 139 consecutive patients undergoing primary angioplasty with implantation of one or more Genous stents, the target lesion revascularisation rate was 3.8% and the rate of definite stent thrombosis was 1.4%. In addition, the rate of cardiac death was 2.9% (four patients), and the target vessel revascularisation was 5.8%.


“STEMI is a highly prothrombotic clinical situation for which the choice of the most appropriate stent remains controversial,” said Melisa Santas-Alvarez, Departamento de Cardiología Intervencionista, Hospital Clínico de Santiago de Compostela, Spain, and first author of the study. “In high-risk situations like STEMI, drug eluting stents can delay healing of the vessel and have been associated with increased risk of thrombosis. We believe that the Genous stent’s ability to accelerate endothelialisation may reduce the risk of stent thrombosis. These results add to the growing body of knowledge confirming the safety and efficacy of Genous in STEMI patients.”


In the GENIA study, the average patient age was 64 ± 13.5 years, and 74.8% of patients were male. Notably, 20.1% of patients had multivessel disease. Patients were prescribed a regimen of antithrombotic and anticoagulant therapy in accordance with the European guidelines for the management of acute myocardial infarction.





Add New Comment

Related Items


Most popular


Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Vascular Solutions introduces two new versions of Turnpike catheters
Thursday, 18 Jun 2015
All three versions of the Turnpike are over-the-wire catheters with an advanced shaft design that provides superior tracking and advancement over a 0.014” guidewire for use in complex coronary and ... Vascular Solutions introduces two new versions of Turnpike catheters

Features


Strut coverage: Optical coherence tomography and new stent technologies
Monday, 20 Jul 2015
Tim Kinnaird explores the risk of stent thrombosis with current technologies, how new technologies may be able to reduce this risk, and how OCT can help to assess this risk. Strut coverage: Optical coherence tomography and new stent technologies

The second generation of drug-eluting stents with biodegradable polymers may have potential advantages
Monday, 06 Jul 2015
Drug-eluting stents with biodegradable polymers have theoretical advantages over drug-eluting stents with permanent polymers—even second-generation drug-eluting stents. The second generation of drug-eluting stents with biodegradable polymers may have potential advantages

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions